Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

被引：0
|
作者：
Mauro, Michael [1 ]
Paquette, Ronald [2 ]
Hehlmann, Rudiger [3 ]
Williams, Loretta A. [4 ]
Goldberg, Stuart L. [5 ]
Michallet, Mauricette [6 ]
Gambacorti-Passerini, Carlo [7 ]
Tang, Derek [8 ]
DeGutis, Irene S. [8 ]
McBride, Ali [8 ]
Parsons, Lori [9 ]
Montelongo, Monica Z. [9 ]
Cortes, Jorge E. [10 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Heidelberg Univ, Heidelberg, Germany
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[6] Ctr Lutte Canc Leon Berard, Lyon, France
[7] Univ Milano Bicocca, Milan, Italy
[8] Bristol Myers Squibb, Princeton, NJ USA
[9] ICON plc, Blue Bell, PA USA
[10] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163080
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
632
引用
收藏
页码：9624 / 9625
页数：2
相关论文
共 50 条
  • [41] Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia
    Shin-ichiro Fujiwara
    Yuya Shirato
    Takashi Ikeda
    Shin-ichiro Kawaguchi
    Yumiko Toda
    Shoko Ito
    Shin-ichi Ochi
    Takashi Nagayama
    Kiyomi Mashima
    Kento Umino
    Daisuke Minakata
    Hirofumi Nakano
    Kaoru Morita
    Ryoko Yamasaki
    Yasufumi Kawasaki
    Miyuki Sugimoto
    Masahiro Ashizawa
    Chihiro Yamamoto
    Kaoru Hatano
    Kazuya Sato
    Iekuni Oh
    Ken Ohmine
    Kazuo Muroi
    Yoshinobu Kanda
    International Journal of Hematology, 2018, 107 : 712 - 715
  • [42] Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy
    Smith, B. Douglas
    Liu, Jun
    Latremouille-Viau, Dominick
    Guerin, Annie
    Fernandez, Daniel
    Chen, Lei
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (05) : 817 - 827
  • [43] Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
    Giordano, Ugo
    Piekarska, Agnieszka
    Prejzner, Witold
    Gil, Lidia
    Zaucha, Jan Maciej
    Kujawska, Joanna
    Dybko, Zuzanna
    Dudek, Krzysztof
    Giebel, Sebastian
    Dybko, Jaroslaw
    BIOMEDICINES, 2025, 13 (01)
  • [44] Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML)
    Santos, Fabio P. S.
    Kantarjian, Hagop
    Fava, Carmen
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Komblau, Steven
    Ravandi, Farhad
    Wierda, William
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1104 - 1104
  • [45] Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib
    Breccia, Massimo
    Palandri, Francesca
    Iori, Anna Paola
    Colaci, Elisabetta
    Latagliata, Roberto
    Castagnetti, Fausto
    Torelli, Giovanni Fernando
    Usai, Sara
    Valle, Veronica
    Martinelli, Giovanni
    Rosti, Gianantonio
    Foa, Robin
    Baccarani, Michele
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2010, 34 (02) : 143 - 147
  • [46] Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Jung, Y. S.
    Kim, M.
    Lee, J. H.
    Kim, D. W.
    Park, H. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (02) : 456 - 458
  • [47] Second-Generation Tyrosine Kinase Inhibitors Combined With Stem Cell Transplantation in Patients With Imatinib-Refractory Chronic Myeloid Leukemia
    Zhao, Yanmin
    Luo, Yi
    Shi, Jimin
    Cai, Zhen
    Huang, He
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 347 (06): : 439 - 445
  • [48] Outcome of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Various Frontline Second-Generation Tyrosine Kinase Inhibitors: A Single-Center Experience
    Lee, Sung-Eun
    Choi, Soo Young
    Kim, Soo-Hyun
    Song, Hye-Young
    Yoo, Hea-Lyun
    Lee, Mi-Young
    Kang, Ki-Hoon
    Hwang, Hee-Jeong
    Jang, Eun-Jung
    Kim, Dong-Wook
    BLOOD, 2015, 126 (23)
  • [49] Using 2(nd) generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia
    Jayakar, Vishal
    SOUTH ASIAN JOURNAL OF CANCER, 2014, 3 (01) : 87 - 91
  • [50] Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
    Bonuomo, Valentina
    Koumantakis, Emanuele
    Grano, Selene
    Berchialla, Paola
    Castagnetti, Fausto
    Martino, Bruno
    Elena, Chiara
    Bocchia, Monica
    Capodanno, Isabella
    Intermesoli, Tamara
    Miggiano, Maria Cristina
    Gambacorti-Passerini, Carlo
    Iurlo, Alessandra
    Lunghi, Francesca
    Luciano, Luigiana
    Abruzzese, Elisabetta
    Carella, Angelo Michele
    Breccia, Massimo
    Ferrara, Felicetto
    Crescenzi, Sabrina Leonetti
    Scappini, Barbara
    De Gobbi, Marco
    Sora, Federica
    Rapezzi, Davide
    Luzi, Debora
    Galimberti, Sara
    Crugnola, Monica
    Scortechini, Anna Rita
    Maggi, Alessandro
    Bonifacio, Massimiliano
    Annunziata, Mario
    Caocci, Giovanni
    Beltrami, Germana
    Cavazzini, Francesco
    Pietrantuono, Giuseppe
    Campiotti, Leonardo
    Stagno, Fabio
    Musolino, Caterina
    Cilloni, Daniela
    Saglio, Giuseppe
    Fava, Carmen
    BLOOD, 2024, 144 : 3162 - 3164
12345